Tag: development

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.

(Oslo/Lista, Norway 18 June 2026) Statkraft and Alcoa have signed two new power agreements securing electricity supply to support continued operation of Alcoa’s aluminium plant at Lista, Norway. The agreements provide a solid and predictable energy foundation for the smelter and help maintain both production and further development at the site.

Production Line 2 at Lista recently completed a successful restart of 31,000 metric tonnes per annum to reach its nameplate capacity of 95,000 metric tonnes for the plant. This marked an important milestone for Alcoa in Norway, with restored capacity and a strengthened industrial presence. Building on this, access to reliable and competitively priced power is essential for continued operations.

Publicity Department of Shenyang Municipal Party Committee

PRESS
RELEASE

Attachment

MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.